In an interview conducted during the 2021 ASCO Annual Meeting, Robert A. Figlin, MD, deputy director, Cedars-Sinai Cancer, shared his expertise on trends in the treatment of patients with genitourinary cancers.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.